The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura-Reference-Cited by-同舟云学术

The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura

Published:2022-04-17 Issue:2 Volume:198 Page:391-396
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Doyle Andrew J.¹^ORCID,Stubbs Matthew J.¹²,Lester Will³,Thomas Will⁴^ORCID,Westwood John‐Paul¹,Thomas Mari¹²,Percy Charles³,Prasannan Nithya¹,Scully Marie¹²

Affiliation:

1. Department of Haematology University College Hospitals London NHS Foundation Trust London UK

2. Cardiometabolic Programme University College London Hospitals Biomedical Research Centre, National Institute for Health Research London UK

3. Department of Haematology University Hospitals Birmingham Birmingham UK

4. Department of Haematology Cambridge University Hospitals NHS Foundation Trust Cambridge UK

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18192

Reference25 articles.

1. Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study

2. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse

3. Redefining outcomes in immune TTP: an international working group consensus report

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of daratumumab in multiresistant immune‐mediated thrombotic thrombocytopenic purpura;British Journal of Haematology;2024-09-04

2. ADAMTS13 in the New Era of TTP;International Journal of Molecular Sciences;2024-07-26

3. IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: PATHOPHYSIOLOGY, DIAGNOSIS AND OPEN ISSUES.;Mediterranean Journal of Hematology and Infectious Diseases;2024-06-29

4. Peak ADAMTS13 activity to assess ADAMTS13 conformation and risk of relapse in immune-mediated thrombotic thrombocytopenic purpura;Blood;2024-06-20

5. Serum sickness in a multiple sclerosis patient treated with ocrelizumab;Journal of Neurology;2023-10-31